The Choice of Either Quetiapine or Aripiprazole as Augmentation Treatment in a European Naturalistic Sample of Patients With Major Depressive Disorder.

Beyond its associations with the presence of comorbid PTSD and DM, aripiprazole augmentation was trend-wise related to the presence of additional psychotic symptoms, a higher MADRS total score at study entry, the employment of AD combination treatment, and higher rates of treatment resistance during the current MDE as well as a longer duration of inpatient hospitalizations (24.4 vs 10.8 weeks in cases of augmentation with quetiapine) and a higher number of MDEs during the lifetime (4.1 vs 3.2 in cases of augmentation with quetiapine), even though the latter finding did not reach statistical significance ( P uncorrected = .089).

also in 111,027 other papers